Revelation Biosciences, Inc. (REVB)
- Previous Close
1.8500 - Open
1.8100 - Bid --
- Ask --
- Day's Range
1.8000 - 1.8900 - 52 Week Range
1.7800 - 39.0000 - Volume
49,518 - Avg. Volume
159,381 - Market Cap (intraday)
3.013M - Beta (5Y Monthly) 0.17
- PE Ratio (TTM)
-- - EPS (TTM)
-0.5300 - Earnings Date Aug 9, 2024 - Aug 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
18.70
Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was founded in 2020 and is based in San Diego, California.
www.revbiosciences.comRecent News: REVB
Performance Overview: REVB
Trailing total returns as of 5/14/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: REVB
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: REVB
Valuation Measures
Market Cap
3.00M
Enterprise Value
9.23M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.45
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-61.08%
Return on Equity (ttm)
-3.12%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-120.25k
Diluted EPS (ttm)
-0.5300
Balance Sheet and Cash Flow
Total Cash (mrq)
11.99M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-4.11M
Research Analysis: REVB
Company Insights: REVB
REVB does not have Company Insights